Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
121 hedge funds and large institutions have $501M invested in Progenics Pharmaceuticals Inc in 2015 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 44 increasing their positions, 31 reducing their positions, and 13 closing their positions.
108% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 13
42% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 31
30% more call options, than puts
Call options by funds: $5.62M | Put options by funds: $4.32M
29% more capital invested
Capital invested by funds: $389M → $501M (+$112M)
13% more funds holding
Funds holding: 107 → 121 (+14)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$9.93M |
| 2 |
RA
Royce & Associates
New York
|
+$9.16M |
| 3 |
State Street
Boston,
Massachusetts
|
+$4.92M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$3.38M |
| 5 |
PCM
Piermont Capital Management
St. Louis,
Missouri
|
+$2.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TM
Tiger Management
New York
|
-$7.71M |
| 2 |
AC
Armistice Capital
New York
|
-$6.87M |
| 3 |
PFC
Phocas Financial Corp
Alameda,
California
|
-$4.27M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$2.34M |
| 5 |
Morgan Stanley
New York
|
-$2.26M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Nomura Holdings
Tokyo,
Japan
| – | -$277K | -46,295 | Closed |
|
|
FMA
127
FNY Managed Accounts
New York
| – | -$254K | -42,000 | Closed |
|
|
PCM
128
Price Capital Management
Lafayette,
Louisiana
| – | -$218K | -36,449 | Closed |
|
|
LP
129
LMR Partners
London,
United Kingdom
| – | -$166K | -27,822 | Closed |
|
130
Squarepoint
New York
| – | -$161K | -26,972 | Closed |
|
|
SCM
131
Stevens Capital Management
Radnor,
Pennsylvania
| – | -$110K | -18,431 | Closed |
|
|
PP
132
Paloma Partners
Greenwich,
Connecticut
| – | -$96K | -16,100 | Closed |
|
133
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1.6K | -265 | -88% |
|
PGNX Hedge Fund Activity: Q2 2015 in Review
121 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q2 2015, worth a combined $501M — up 29% from $389M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new PGNX positions and 13 closed out — a net gain of 14 holders — while 44 added to existing stakes and 31 trimmed.
The largest buyer was Millennium Management, adding an estimated $9.93M. The largest seller was Tiger Management, exiting entirely with an estimated $7.71M sold.
- 121 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q2 2015, up from 107 in Q1 2015.
- Funds reported $501M of Progenics Pharmaceuticals Inc stock for Q2 2015, up 29% quarter-over-quarter.
- 27 funds opened new Progenics Pharmaceuticals Inc positions in Q2 2015 and 13 closed out, a net change of +14 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q2 2015 was Millennium Management, an estimated $9.93M added.
- The largest Progenics Pharmaceuticals Inc seller in Q2 2015 was Tiger Management, an estimated $7.71M sold.
Based on aggregated 13F filings for Q2 2015.